Inhibition of the voltage-dependent K+ current by the class Ic antiarrhythmic drug flecainide in rabbit coronary arterial smooth muscle cells

Clinical and Experimental Pharmacology & Physiology
Jin Ryeol AnWon Sun Park

Abstract

This study examined the inhibitory effect of flecainide, a class 1c antiarrhythmic agent (Na+ channel blocker), on voltage-dependent K+ (Kv) channels in smooth muscle cells isolated from coronary arteries. Flecainide decreased the vascular Kv channel current in a dose-dependent manner with an IC50 value of 5.90 ± 0.87 μmol/L and a Hill coefficient of 0.77 ± 0.06. Although the steady-state activation curve was not affected by flecainide, it shifted the steady-state inactivation curves toward a more negative potential. Application of train pulses such as 1 or 2 Hz did not change the flecainide-induced inhibition of Kv channels, indicating that the inhibitory effect of flecainide was not use-dependent. Using perforated-patch clamp experiments, we found that inhibition of Kv channels by flecainide caused membrane depolarization. Together, these results suggest that flecainide inhibits Kv channels in a concentration-dependent, but not use-dependent manner by changing the inactivation gating properties. Furthermore, Kv channel inhibition by flecainide occurs regardless of Na+ channel inhibition.

References

May 1, 1989·Journal of Clinical Pharmacology·H FruminM Rubenfire
Feb 1, 1985·Journal of the American College of Cardiology·N IkedaO Hauswirth
Feb 27, 1984·The American Journal of Cardiology·D C KvamJ R Schmid
Feb 27, 1984·The American Journal of Cardiology·J Morganroth, L N Horowitz
Dec 1, 1981·The American Journal of Cardiology·H J DuffR L Woosley
Aug 4, 1995·European Journal of Pharmacology·T YamagishiN Taira
Apr 1, 1995·The American Journal of Physiology·M T Nelson, J M Quayle
Feb 15, 1994·European Journal of Pharmacology·D S KrafteA M Ezrin
Jan 15, 1999·Acta Physiologica Scandinavica·N B Standen, J M Quayle
Jan 21, 2000·Hypertension·W F Jackson
May 2, 2003·British Journal of Pharmacology·Ricardo CaballeroStanley Nattel
Jul 11, 2006·Biochemical and Biophysical Research Communications·Young Min BaeSung Il Cho
Jun 17, 2008·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Eun A KoWon Sun Park
Oct 20, 2009·Progress in Biophysics and Molecular Biology·Eun A KoJin Han
Jun 17, 2010·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Won Sun ParkEun A Ko
Dec 9, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Etienne AliotJuan Tamargo

❮ Previous
Next ❯

Citations

Jul 23, 2019·Clinical and Experimental Pharmacology & Physiology·Hongliang LiWon Sun Park

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.